Thursday, 15 October 2026European Markets

GLINTT And MELEXIS Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(VIANEWS) - GLINTT (GLINT.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Technology sector.

Financial Asset Price Forward Dividend Yield Return on Equity
GLINTT (GLINT.LS) €0.50 7.1% 6.67%
MELEXIS (MELE.BR) €73.35 4.92% 39.77%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GLINTT (GLINT.LS)

7.1% Forward Dividend Yield and 6.67% Return On Equity

Glintt Global, S.A. provides IT consulting services for banking, insurance, public administration, and utilities sectors in Portugal, Spain, and Angola. It operates through two segments: Health and Other Markets. The company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. It licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. In addition, the company implements ERPs, integrates internet systems, and develops tailor-made applications services. Further, the company develops, implements, and integrates partner platforms with emphasis on the BPM, ERP, BI and mobility solutions; and integrates IT infrastructures, as well as support for networking, security, storage systems, and database management. The company was formerly known as Glintt - Global Intelligent Technologies, S.A. and changed its name to Glintt Global, S.A. in July 2024. Glintt Global, S.A. was incorporated in 1995 and is based in Sintra, Portugal. Glintt Global, S.A. operates as a subsidiary of Farminveste - Investimentos, Participações E Gestão S.A.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.05.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 9.92. Meaning, the purchaser of the share is investing €9.92 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.67%.

Moving Average

GLINTT's worth is higher than its 50-day moving average of €0.49 and way above its 200-day moving average of €0.42.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jun 25, 2024, the estimated forward annual dividend rate is 0.03 and the estimated forward annual dividend yield is 7.1%.

More news about GLINTT.

2. MELEXIS (MELE.BR)

4.92% Forward Dividend Yield and 39.77% Return On Equity

Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, current, latch and switch, inductive position, speed, pressure, tire monitoring, temperature, and optical sensors ICs and time-of-flight; embedded motor, smart, fan and pump, smart LED, and pre-driver ICs; embedded lighting; and LIN transceiver, CAN transceiver, and RFID transceivers. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.

Earnings Per Share

As for profitability, MELEXIS has a trailing twelve months EPS of €5.17.

PE Ratio

MELEXIS has a trailing twelve months price to earnings ratio of 14.19. Meaning, the purchaser of the share is investing €14.19 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 39.77%.

More news about MELEXIS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com